Objective To evaluate the effect of regimens containing bevacizumab on platelet parameters of patients with metastatic non-small cell lung cancer (NSCLC). Methods A total of 58 patients with metastatic NSCLC were recruited, and all of them were given Beva-cizumab chemotherapy. Their clinical data were retrospectively analyzed. Their platelet counts (PLTs), platelet distribution width (PDW), mean platelet volume (MPV), platelet–large-cell ratio (P-LCR), and platecrit (PCT) values at baseline and after three months of chemo-therapy were recorded in the SPSS 18.0 program. Results PCT significantly decreased during treatment with bevacizumab (P=0.024). Subgroup analysis revealed that PLTs significantly decreased in the male group and ≥60-year-old group (P=0.022, 0.012). The PCT was significantly diminished in the male group and first-line chemotherapy group (P=0.015, 0.004). After treatment, one case of subcutaneous bleeding (3.03%) occurred in the first-line chemotherapy group, and one case of pulmonary hemorrhage (4.00%) occurred in the second line chemotherapy group. The total incidence of bleeding was 3.44%. Conclusion The chemotherapy regimens containing bevacizumab could decrease PCT of patients with metastatic NSCLC.%目的 观察含贝伐珠单抗化疗方案对转移性非小细胞肺癌患者血小板参数的影响.方法 回顾性分析接受含贝伐珠单抗化疗方案的58例转移性非小细胞肺癌患者的临床资料,分析比较患者化疗前和化疗后3个月的血小板数量、血小板压积变化,并对出血风险进行评估.结果 与化疗前相比,接受含贝伐珠单抗化疗患者的血小板压积、白细胞显著下降(P=0.024).亚组分析显示男性患者以及≥60岁患者亚组化疗后的血小板数量显著性降低(P=0.022, 0.012);男性患者和接受一线化疗患者亚组化疗后的血小板压积显著性降低(P=0.015, 0.004).化疗后一线化疗组发生1例皮下出血(3.03%),二线化疗组发生1例肺出血(4.00%),出血的总发生率为3.44%.结论 含贝伐珠单抗化疗方案可以显著降低转移性非小细胞肺癌患者的血小板压积.
展开▼
